Tanvir Ahmed, MBBS, PhD

Tanvir Ahmed, MBBS, PhD, is a principal scientist at the Center for Advanced Molecular and Immunological Therapies, where he leads research focused on the development of mRNA-based personalized cancer vaccines. His primary work involves identifying tumor-specific neoantigens and designing precision immunotherapies that harness the body’s immune system to selectively target cancer cells. 

Ahmed previously served as director of drug development at VBI Vaccines Inc., where he led multidisciplinary teams in research, cGMP manufacturing and regulatory affairs. He played a key role in advancing next-generation vaccine platforms, including lipid nanoparticle-mRNA, enveloped virus-like particles, recombinant protein-based technologies and thermostable formulations.

He earned his MBBS (MD equivalent) from the University of Dhaka in Bangladesh and began his career as a research physician at the International Centre for Diarrhoeal Disease Research, Bangladesh, where he conducted several GCP-compliant Phase I/II clinical trials on enteric vaccines in low-resource settings. He completed his doctorate in enteric vaccine development at the University of Gothenburg in Sweden and pursued postdoctoral training in cellular and molecular immunology at Tufts University.

Ahmed has more than 25 years of experience spanning preclinical research, clinical development, manufacturing and regulatory strategy. He remains passionate about pushing the boundaries of vaccine and immunotherapy innovation to improve patient outcomes and shape the future of precision medicine.